Welcome to our dedicated page for Petvivo Hldgs SEC filings (Ticker: PETV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PetVivo Holdings, Inc. (PETV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nevada corporation with Commission File Number 001-40715, PetVivo submits current reports, periodic reports and exhibits that document material events, governance changes, financing transactions and investor communications related to its animal health and veterinary AI businesses.
For PetVivo, Form 8-K current reports are particularly relevant. Recent 8-K filings have covered topics such as the appointment and resignation of directors, changes in board size, entry into note conversion agreements with shareholders, and the furnishing of investor presentations under Regulation FD. These filings can give investors insight into PetVivo’s corporate governance, capital structure adjustments and how it communicates its strategy around products like SPRYNG with OsteoCushion technology, PrecisePRP and the PetVivo.ai platform.
In addition to current reports, investors may consult PetVivo’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for detailed information on business operations, risk factors, financial statements and segment discussions related to its veterinary medical devices, regenerative products and AI initiatives. Form 4 and other ownership filings, when filed, can be used to monitor equity transactions by directors, officers and significant shareholders.
Stock Titan enhances these filings with AI-powered summaries that explain key points in clear language, helping readers interpret complex disclosures such as note conversions, licensing agreements or board changes. Real-time updates from EDGAR ensure that new PETV filings appear promptly, while structured access to exhibits like investor presentations allows users to review the same materials referenced in PetVivo’s Regulation FD communications.
A.L. Sarroff Fund, LLC, a more than 10% owner of PetVivo Holdings, Inc. (PETV), filed a Form 4 detailing extensive insider activity in 2024. The fund reported multiple open-market purchases of PetVivo common stock between April 5 and October 15, 2024 at prices ranging from $0.40 to $1.06 per share, along with several warrant-related transactions, including exercises and new warrant purchases.
These transactions included warrant exercises that delivered shares, such as 770,767 common shares on September 26, 2024, and warrant acquisitions in February, April, May, June, and July 2024. Following the most recent trade on October 15, 2024, the fund directly beneficially owned 6,610,930 shares of PetVivo common stock, with additional common stock and warrants reported as indirectly owned, including securities held by the spouse of Alan L. Sarroff. Alan L. Sarroff is the chief executive officer and managing member of the fund and is deemed to beneficially own and have sole voting and dispositive power over its securities.
A.L. Sarroff Fund, LLC, a 10% owner of PetVivo Holdings, Inc., reported several equity transactions. On October 26, 2023, the fund acquired 164,340 shares of common stock at $0.73 per share, bringing its holdings to 1,748,251 common shares.
On December 15, 2023, the fund purchased an additional 111,112 common shares at $0.90 per share, increasing its position to 1,859,363 common shares. The same day, it bought 111,112 warrants with a $1.50 exercise price, each warrant exercisable for one share of common stock and expiring on December 15, 2026. A footnote states that Alan L. Sarroff, as Chief Executive Officer and Managing Member of the fund, is deemed to beneficially own and have sole voting and dispositive power over the fund’s securities.
PetVivo Holdings has a new major shareholder group disclosed in a Schedule 13D. A.L. Sarroff Fund, LLC, together with Alan and Eileen Sarroff, report beneficial ownership of 13,933,204 shares of common stock, representing approximately 36.1% of the company based on 33,580,630 shares outstanding as of November 14, 2025, and assuming the exercise of warrants to purchase 5,005,008 shares.
All of these shares are held with shared voting and dispositive power; none of the reporting persons has sole power over the shares. The position was built for investment purposes through open‑market purchases and private placements using personal funds. The reporting persons state they will continue to review their investment and may increase or decrease their holdings or economic exposure, including through derivatives such as swaps or options, but they do not currently outline specific corporate actions beyond standard possibilities referenced in Schedule 13D.
PetVivo Holdings, Inc. reported that its Board of Directors recognized the resignation of director Michael Eldred, effective January 9, 2026. The company stated that his resignation was not due to any disagreement with the company on operations, policies, or practices. In response, the Board decided to reduce its size from eight to seven directors and will not fill the resulting vacancy at this time. The Board formally expressed its appreciation for Mr. Eldred’s service and contributions.
PetVivo Holdings’ Chief Financial Officer, Garry Lowenthal, reported an insider stock grant. On 12/11/2025, a corporation he owns received 72,500 shares of restricted common stock at $1.05 per share as compensation for his past performance. After this award, he indirectly beneficially owns 740,467 shares of PetVivo common stock through that corporation.
PetVivo Holdings Chief Executive Officer and director John Lai indirectly acquired 72,500 shares of the company’s common stock on 12/11/2025 at $1.05 per share. The transaction was a grant of restricted common stock to a corporation he owns, provided as compensation for his past performance by converting a previously accrued bonus into equity.
After this award, Lai beneficially owned 2,168,210 shares of PetVivo common stock, held indirectly through the corporation. This increases the portion of his compensation tied to the company’s stock performance.
PetVivo Holdings (PETV) director reports open-market share purchases. Director Robert Rudelius bought three blocks of the company's common stock on 11/24/2025, acquiring 3,000 shares at $1.08, 523 shares at $1.05, and 500 shares at $1.28. The filing states these were routine investment transactions and were not made under any compensatory or issuer-sponsored plan.
Following these transactions, Rudelius beneficially owned 318,392 shares directly and an additional 21,000 shares indirectly through a corporation. This Form 4 reflects his updated ownership position and confirms that the purchases were personal investments in PetVivo Holdings stock.
PetVivo Holdings, Inc. (PETV) disclosed a new director, Joshua David Ruben, in a Form 3 initial beneficial ownership report. The filing shows he holds 0 shares of PetVivo common stock in direct ownership and reports no derivative securities such as options or warrants. This is a routine disclosure required when an individual becomes a director or otherwise subject to Section 16 reporting.
PetVivo Holdings (PETV) reported Q2 FY2026 results. Revenue was $303,284 versus $200,720 a year ago, driven mainly by sales to Vedco after prior distributor agreements were terminated. Gross profit was $220,058. The company recorded a net loss of $3,007,809 for the quarter and $5,318,846 for the six months.
Cash was $767,914 and stockholders’ equity $4,182,972 at September 30, 2025. Total liabilities fell to $1,075,297 from $5,119,947, reflecting the conversion of $1,850,000 in convertible notes plus interest into 3,669,806 shares and the elimination of derivative liabilities. Operating cash outflow was $3,828,209 for the six months, partly offset by $4,361,829 of financing inflows, including receipt of the remaining $4,400,000 under the $5,000,000 Series B Preferred subscription (10% annual dividend payable in stock).
The company added two licensing assets: VetStem PRP ($2,000,000 fee) and an AI software license ($800,000 paid in stock). Shares outstanding were 33,580,630 as of November 14, 2025. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
PetVivo Holdings, Inc. (PETV) furnished an investor presentation as Exhibit 99.1 via an 8‑K. The Company states representatives may use this presentation at investor conferences and other forums, and it may also appear on the corporate website.
The information is provided under Regulation FD, Item 7.01, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced. The exhibit is titled “PetVivo Holdings, Inc. Investor Presentation” and is dated November 2025.